AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
December 22, 2023 07:00 ET
|
AlloVir Inc.
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety...
AlloVir Reports Third Quarter 2020 Financial Results
November 10, 2020 07:00 ET
|
AlloVir Inc.
- Completed initial public offering raising $317.7M in gross proceeds - Viralym-M (multi-virus-specific T cell therapy) registrational study in lead indication in virus-associated hemorrhagic...
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting
November 04, 2020 13:33 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that...
Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
October 21, 2020 07:30 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that health outcomes analyses to be presented at IDWeek™ 2020...
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
September 17, 2020 09:49 ET
|
AlloVir Inc.
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients - Proof-of-concept clinical trial with ALVR109 to...
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer
September 08, 2020 16:15 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced the appointment of Ercem Atillasoy, M.D., as the company’s Chief...
AlloVir Reports Second Quarter 2020 Financial Results
September 02, 2020 07:30 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020. ...
AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
August 25, 2020 07:30 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th...
AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
August 03, 2020 16:30 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offering of...
AlloVir Announces Pricing of Upsized Initial Public Offering
July 30, 2020 07:32 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offering of...